✦ LIBER ✦

Adjuvant Docetaxel for Node-Positive Breast Cancer

✍ Scribed by Martin, Miguel; Pienkowski, Tadeusz; Mackey, John; Pawlicki, Marek; Guastalla, Jean-Paul; Weaver, Charles; Tomiak, Eva; Al-Tweigeri, Taher; Chap, Linnea; Juhos, Eva; Guevin, Raymond; Howell, Anthony; Fornander, Tommy; Hainsworth, John; Coleman, Robert; Vinholes, Jeferson; Modiano, Manuel; Pinter, Tamas; Tang, Shou C.; Colwell, Bruce; Prady, Catherine; Provencher, Louise; Walde, David; Rodriguez-Lescure, Alvaro; Hugh, Judith; Loret, Camille; Rupin, Matthieu; Blitz, Sandra; Jacobs, Philip; Murawsky, Michael; Riva, Alessandro; Vogel, Charles

Book ID: 121453349
Publisher: Massachusetts Medical Society
Year: 2005
Tongue: English
Weight: 138 KB
Volume: 352
Category: Article
ISSN: 0096-6762
DOI: 10.1056/NEJMoa043681

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

1–48 Adjuvant Docetaxel for Node-Positiv

1–48 Adjuvant Docetaxel for Node-Positive Breast Cancer

✍ Seidman, A.D. 📂 Article 📅 2006 🏛 Elsevier Science 🌐 English ⚖ 44 KB

Sequential Adjuvant Epirubicin-Based and

Sequential Adjuvant Epirubicin-Based and Docetaxel Chemotherapy for Node-Positive Breast Cancer Patients: The FNCLCC PACS 01 Trial

✍ Denlinger, C.S.; Goldstein, L.J. 📂 Article 📅 2007 🏛 Elsevier Science 🌐 English ⚖ 68 KB

Cost-effectiveness analysis of adjuvant

Cost-effectiveness analysis of adjuvant docetaxel, doxorubicin, and cyclophosphamide (TAC) for node-positive breast cancer: modeling the downstream effects

✍ Heather-Jane Au; Kamran Golmohammadi; Tallal Younis; Shailendra Verma; Stephen C 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 307 KB

Sequential docetaxel as adjuvant chemoth

Sequential docetaxel as adjuvant chemotherapy for node-positive or/and T3 or T4 breast cancer: clinical outcome (Mansoura University)

✍ H. Sakr, R. H. Hamed, A. H. Anter, T. Yossef 📂 Article 📅 2013 🏛 Springer US 🌐 English ⚖ 204 KB

Cost–effectiveness analysis of adjuvant

Cost–effectiveness analysis of adjuvant therapy for node positive breast cancer in Korea: docetaxel, doxorubicin and cyclophosphamide (TAC) versus fluorouracil, doxorubicin and cyclophosphamide (FAC)

✍ Sang Gyu Lee; Young Geon Jee; Hyun Chul Chung; Sung-Bae Kim; Jungsil Ro; Young-H 📂 Article 📅 2008 🏛 Springer US 🌐 English ⚖ 231 KB

Improvement in Disease-Free Survival wit

Improvement in Disease-Free Survival with Doxorubicin/Docetaxel/Cyclophosphamide (TAC) Versus 5-Fluorouracil/Doxorubicin/Cyclophosphamide (FAC) as Adjuvant Therapy for Node-Positive Breast Cancer

✍ Amy I. D'Orazio; Joyce O'Shaughnessy 📂 Article 📅 2002 🏛 CIG Media Group, LP. 🌐 English ⚖ 96 KB